Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
UCB Pharma
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with CD22-positive ALL with either refractory disease (i.e. disease progression or no response while receiving their most recent prior anti-cancer therapy), or relapsed disease (i.e. response to their most recent prior anti-cancer therapy with subsequent relapse). Subjects enrolled in the Phase 2 portion of the study must be due to receive salvage 2 or later therapy.
Subjects with Philadelphia chromosome-positive (Ph+) ALL must have failed standard treatment with at least one tyrosine kinase inhibitor.
Adequate renal and hepatic function, and negative pregnancy test for women of childbearing potential.
You may not be if
Subjects with isolated extramedullary relapse or active central nervous system (CNS) leukemia.
Prior allogeneic hematopoietic stem cell transplant (HSCT) or other anti-CD22 immunotherapy within 4 months, or active graft versus host disease (GvHD) at study entry.
Evidence or history of veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS).
Clareo Health | Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
